1 Reason Every Investor Should Know About Novo Nordisk (NVO)

It's no secret that Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are toughing it out in the battle of the weight loss drug market. It's also not lost on many investors that Eli Lilly's obesity drug, Zepbound, is winning market share away from Novo Nordisk's offering, Wegovy. Despite Wegovy being approved by the Food and Drug Administration (FDA) to treat obesity first in 2021 and Zepbound gaining approval more than two years later in 2023,  Zepbound's superior efficacy and Novo Nordisk suffering supply issues with Wegovy have meant the company has lost a bit of the battle.That said, both Wegovy and Zepbound are delivered subcutaneously (by injection under the skin), but there's another battle brewing over oral weight loss drugs.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool